NextFin

EQT Enlists Goldman and Morgan Stanley for €7 Billion WS Audiology Exit

Summarized by NextFin AI
  • EQT AB has engaged Goldman Sachs and Morgan Stanley to explore strategic options for WS Audiology, potentially valuing the company at approximately €7 billion ($7.5 billion).
  • WS Audiology is navigating a complex financial landscape with high leverage and a recent return to profitability, as Fitch Ratings maintains a 'B' rating with a stable outlook.
  • For the 2025/26 fiscal year, WS Audiology anticipates organic revenue growth of 0% to 4%, with an expected EBITDA margin expansion of about one percentage point due to cost-cutting measures.
  • The hearing-aid industry is highly consolidated, with WS Audiology competing against major players, while EQT aims to leverage its online retail platform to redefine market dynamics.

NextFin News - EQT AB has engaged Goldman Sachs Group Inc. and Morgan Stanley to explore strategic options for WS Audiology A/S, including a potential initial public offering or a private sale that could value the hearing-aid manufacturer at approximately €7 billion ($7.5 billion). The Swedish private equity firm, which formed the company through the 2019 merger of Sivantos and Widex, is testing the appetite for healthcare assets as the European IPO market shows signs of a tentative recovery. According to Bloomberg, the deliberations are in the early stages, and the final valuation will depend on market conditions and the company’s ability to sustain its recent margin improvements.

The move comes as WS Audiology navigates a complex financial landscape characterized by high leverage and a recent return to profitability. Fitch Ratings, which affirmed the company’s 'B' rating with a stable outlook in March 2026, noted that while the business profile remains solid, its credit profile is constrained by weaker free cash flow and high debt levels. Fitch analysts project that the company’s EBITDA leverage will only gradually fall toward 6x by 2028, a trajectory that hinges on the successful rollout of new product lines and a sustained return to organic growth. This cautious credit perspective serves as a necessary counterweight to the more optimistic valuation targets circulating in the M&A market.

For the 2025/26 fiscal year, WS Audiology has guided for organic revenue growth of 0% to 4%, reflecting what management describes as an "uncertain macroeconomic environment." Despite these headwinds, the company expects its EBITDA margin to expand by approximately one percentage point, supported by cost-cutting measures implemented in 2024 and 2025. S&P Global Ratings has echoed this sentiment, forecasting an adjusted EBITDA margin of 17.5% to 18.0% for 2025. These internal efficiencies are critical for EQT as it seeks to justify a €7 billion price tag to potential public investors or private equity peers who are increasingly disciplined about cash flow generation.

The hearing-aid industry remains a highly consolidated "pure play" sector, where WS Audiology competes against giants like Sonova Holding AG and Demant A/S. While the long-term demographics of an aging global population provide a structural tailwind, the sector has faced pressure from the rise of over-the-counter (OTC) hearing aids and shifting retail dynamics. EQT’s decision to hire banks now suggests a desire to capitalize on the company’s status as a leading online retailer through its audibene platform, which has helped it redefine the competitive landscape across more than 125 countries.

A successful exit would mark a significant milestone for EQT’s healthcare portfolio, yet the path to a €7 billion valuation is not without obstacles. Market participants remain wary of the "valuation gap" that has plagued recent European listings, where private equity expectations have frequently clashed with public market skepticism regarding high-leverage structures. If a public listing fails to materialize, EQT may pivot toward a minority stake sale or a secondary buyout, though the pool of buyers capable of absorbing a multi-billion-euro healthcare asset remains limited in the current interest rate environment.

Explore more exclusive insights at nextfin.ai.

Insights

What are key concepts behind WS Audiology's formation?

What led to the merger of Sivantos and Widex in 2019?

What is the current market situation for WS Audiology?

What feedback have users provided regarding WS Audiology products?

What industry trends are affecting the hearing-aid market today?

What are the latest updates regarding WS Audiology's IPO exploration?

What are the recent policy changes impacting the healthcare asset market?

What is the future outlook for WS Audiology's market position?

What challenges does WS Audiology face in achieving its €7 billion valuation?

What controversies surround the rise of over-the-counter hearing aids?

How does WS Audiology compare to competitors like Sonova and Demant?

What historical cases can be linked to WS Audiology's current financial strategy?

What limitations are affecting investor confidence in WS Audiology?

What implications does high leverage have for WS Audiology's growth potential?

How has the competitive landscape changed for WS Audiology since its founding?

What role does the audibene platform play in WS Audiology's strategy?

What potential paths could EQT take if the IPO does not proceed?

What are the projections for WS Audiology's EBITDA margin through 2025?

What factors contribute to the 'valuation gap' in European listings?

Search, ask or analyze anything...